Acrux begins anti-nausea trial
Wednesday, 02 March, 2005
Acrux (ASX:ACR) has commenced dosing in a Phase I clinical trial utilising its MDTS transdermal spray to deliver anti-nausea drug granisetron. The pharmacokinetics trial will compare absorption of the drug, which is used to treat nausea in chemotherapy patients, against that of an oral formulation in six healthy volunteers.
"Prevention of nausea during chemotherapy with a product that does not require injections or tablets would help minimise distress for cancer patients," said Acrux CEO Igor Gonda. Brisbane-based CRO Q-Pharm is conducting the trial in its clinical trials facilities at the Royal Brisbane Hospital for Acrux subsidiary Acrux DDS.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...